OPKO HEALTH Reports Q2 FY2023 Earnings Results on June 30, 2023

August 28, 2023

🌥️Earnings Overview

On June 30, 2023, OPKO HEALTH ($NASDAQ:OPK) reported their Q2 earnings results for FY2023. Total revenue for the quarter decreased 14.4% year-over-year to USD 265.4 million, while net income was a marked improvement from the -101.6 million reported in the same period of the prior year, at -19.6 million.

Stock Price

The stock opened at $1.7 and closed at $1.8, representing a 5.1% increase from its last closing price of $1.8. This significant jump in stock price was due to the positive financial performance of the company in the Q2 earnings report. The strong results were attributed to the company’s diversified portfolio of products and services in the healthcare sector.

In addition, OPKO HEALTH also reported strong progress in its research and development initiatives. A number of promising new products and services are expected to be released in the near future, which could further add to the company’s success. Furthermore, OPKO HEALTH is actively engaged in strategic partnerships with other healthcare providers to expand its presence in the marketplace. Overall, OPKO HEALTH has reported impressive earnings results for Q2 FY2023, which has been reflected in the stock price appreciation on Thursday. The company is well-positioned to capitalize on its strong performance and momentum in the healthcare sector, and investors can expect further growth in the upcoming quarters. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Opko Health. More…

    Total Revenues Net Income Net Margin
    868.08 -209.23 -24.5%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Opko Health. More…

    Operations Investing Financing
    -86.87 -25.76 8.93
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Opko Health. More…

    Total Assets Total Liabilities Book Value Per Share
    2.16k 623.55 1.99
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Opko Health are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -3.5% -28.7%
    FCF Margin ROE ROA
    -12.7% -10.1% -7.2%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    GoodWhale has analyzed the financials of OPKO HEALTH and found it to have a low health score of 3/10. This means that it is less likely to pay off debt and fund future operations due to its cashflows and debt. Further, our Star Chart analysis of the company showed it to be strong in asset, medium in profitability, and weak in dividend and growth. We classified OPKO HEALTH as an ‘elephant’, which is a type of company that is rich in assets after deducting off liabilities. Given its financial status and asset strength, OPKO HEALTH would be attractive to investors looking for short-term gains, such as value investors who are seeking to capitalize on its current asset value. On the other hand, those looking for capital appreciation through long-term growth may stay away from this company as its growth prospects seem limited. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company operates through four segments: Diagnostics, Biopharmaceuticals, Pharmaceuticals, and Corporate. The Diagnostics segment offers tests and products for the detection of disease markers, such as PSA tests for the detection of prostate cancer, genetic tests, and tests for the detection of infectious diseases. The Biopharmaceuticals segment focuses on the development and commercialization of biologics products, such as human growth hormone therapy, gene therapy, and vaccines. The Pharmaceuticals segment focuses on the development and commercialization of small molecule drugs. The Corporate segment represents the general and administrative expenses of the company.

    – Psychemedics Corp ($NASDAQ:PMD)

    Psychemedics Corporation is a biotechnology company that develops and markets products and services for the detection of drugs of abuse through the analysis of hair samples. The company was founded in 1987 and is headquartered in Canton, Massachusetts.

    – IDenta Corp ($OTCPK:IDTA)

    Denta Corp is a dental products company with a market cap of 1.42M as of 2022. The company has a Return on Equity of -10.42%. The company manufactures and sells dental products such as toothpaste, toothbrushes, floss, and mouthwash. The company also provides dental services such as teeth whitening and cleaning.

    – Eurofins Scientific SE ($LTS:0MV5)

    Eurofins Scientific SE is a world leader in food, environmental, pharmaceutical and cosmetics products testing. It has a market cap of 12.5B as of 2022 and a return on equity of 12.32%. The company provides an extensive range of testing services to ensure the safety and quality of food, pharmaceutical and cosmetics products. It also offers environmental testing services to monitor and protect the environment from pollution.


    OPKO HEALTH reported their Q2 FY2023 earnings results on June 30 2023. Total revenue for the quarter was USD 265.4 million, a decrease of 14.4% year-over-year. Net income was USD -19.6 million, a significant improvement from the -101.6 million reported the same period last year. This news caused the stock price to increase, providing a good investment opportunity. Investors will want to continue monitoring OPKO HEALTH’s earnings results in the coming quarters to determine whether the company can maintain positive growth.

    Additionally, investors should look to the company’s balance sheet and other financials to gauge the strength of their overall operations. With an improved net income and increasing stock price, OPKO HEALTH looks like a potential winner for investors.

    Recent Posts

    Leave a Comment